The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

Haemonetics expects the deal to increase its short- and long-term revenue. The all-cash transaction should close by January 2024.

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

The advanced algorithm achieved a sensitivity of 93% and specificity of 98%. It was trained to identify up to five different valvular diseases at the same time from a single audio clip.

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR. 

The announcement came just weeks after an FDA subcommittee voted in favor of approval. 

Preventing sudden cardiac arrest involves managing risk factors such as hypertension, hyperlipidemia and diabetes. We spoke to Christine Albert, MD, about this and much more at ESC 2023.